Pharma News
22 Mar 2026 to 28 Mar 2026
Mar 27, 2026
NMC advisory declares stem cell treatment for autism unlawful - Drug Regulation
The National Medical Commission (NMC) has declared stem cell therapy illegal for treating Autism Spectrum Disorder and cerebral palsy in routine practice, following Supreme Court directions and ICMR guidelines. This advisory was issued on March 25, 2026, emphasizing the need for adherence to established medical practices.
Mar 27, 2026
Intelligent Bio Solutions Expands European Intellectual Property Holdings with Its Eighth Patent Approval
Intelligent Bio Solutions Inc. (Nasdaq: INBS) has secured its eighth European patent, EP3752831, enhancing its fingerprint sweat drug testing technology. This patent protects advancements in analyzing substances by correlating chemical findings with fingerprint deposition volume, improving testing accuracy. The company's non-invasive testing solution offers a rapid alternative to traditional methods, targeting safety-critical sectors.
Mar 27, 2026
Novo Nordisk takes legal action against Dr. Reddy's in India over trademark dispute involving Ozempic and Olymviq.
Novo Nordisk is intensifying legal efforts to protect its semaglutide products, Ozempic and WeGovy, from Indian generic competitors. The company has filed a lawsuit against Dr Reddy’s Laboratories (DRL) for trademark infringement over the name 'Olymviq'. DRL has agreed to halt further production under this name while also launching a semaglutide formulation called 'Obeda'.
Mar 26, 2026
Lexaria Bioscience Grows Its Patent Portfolio with Five New Approvals, Featuring Diabetes Research...
Lexaria Bioscience Corp. has secured five new patents, including two for diabetes treatment using GLP-1 drugs, enhancing its intellectual property portfolio. The patents, granted in Japan and Australia, cover methods utilizing Lexaria’s DehydraTECH technology. CEO Richard Christopher highlighted their significance amid intense competition in the GLP-1 industry. Lexaria now holds 65 patents globally, bolstering its market position.
Mar 26, 2026
Q4 Summary of Branded Pharmaceutical Stocks: A Look at Collegium's Performance ... - TradingView
In Q4 earnings, Collegium Pharmaceutical (COLL) reported $205.4 million in revenue, up 12.9% year-on-year, but missed EPS estimates, leading to a 26.8% stock decline. Eli Lilly (LLY) excelled with $19.29 billion in revenue, up 42.6%, while Pfizer (PFE) and Zoetis (ZTS) had mixed results. The branded pharmaceutical sector faces challenges from regulatory scrutiny and patent cliffs.
Mar 26, 2026
With the expiration of patents on weight-loss medications, both doctors and patients eagerly await the arrival of more affordable generic options. - CBC
Novo Nordisk's patents for Ozempic and Wegovy, drugs containing semaglutide, have expired, paving the way for generics in Canada. Patients and doctors are eagerly awaiting cheaper alternatives, which could lower costs from $300-$400 to around $100 monthly. Health Canada is reviewing nine generic semaglutide medications, with potential availability by summer or fall.
Mar 26, 2026
'Increased monitoring of illegal weight-loss medications' | Hindustan Times Haryana
India's drug regulator has intensified monitoring of unauthorized weight-loss drug sales following the launch of cheaper generic versions of Ozempic and Wegovy by local companies, including Dr Reddy's, Zydus, and Sun Pharma. The generics, containing semaglutide, are up to 70% cheaper than Novo Nordisk’s products, raising concerns over potential misuse and confusion among prescribers.
Mar 26, 2026
Reducing Prices of Generic Medications to Encourage the Development of New Innovative Drugs
The Ministry of Health and Welfare has approved a comprehensive reform of the drug pricing system, reducing generic drug prices from 53.55% to 45% and shortening the listing period for new rare disease drugs to 100 days. This initiative aims to enhance patient access, support R&D, and improve the domestic pharmaceutical ecosystem.
Mar 26, 2026
Weight loss medications: successful yet costly, though this may soon improve.
The Lancet's cover story highlights the evolving landscape of anti-obesity treatments, focusing on the impending patent expirations of semaglutide (Ozempic®, Wegovy®) and the rise of affordable biosimilars. With over a billion people affected by obesity, experts emphasize the need for equitable access to these therapies, as the market could reach $150 billion by 2035. The WHO advocates for systemic solutions to ensure broader availability.
Mar 26, 2026
US Senators called on federal regulators to take action against the unlawful online distribution of abortion pills.
U.S. Senators, led by Bill Cassidy, urged federal regulators to combat illegal online sales of abortion pills. They emphasized the need for compliance from chemical abortion drug manufacturers with FDA regulations to ensure safety and legality in the distribution of these medications.
Mar 26, 2026
Novo Nordisk evaluates a drug developed in China for obesity and diabetes amid increasing competition.
Novo Nordisk's new diabetes and weight loss drug, UBT251, shows promising results in a mid-stage trial in China, outperforming semaglutide in blood sugar reduction and weight loss. However, rival Eli Lilly's retatrutide is ahead in development, potentially limiting UBT251's market impact. Novo Nordisk has partnered with The United Laboratories and plans further global trials, with results expected in 2027.
Mar 26, 2026
With the expiration of patents on weight-loss medications, both doctors and patients eagerly await the arrival of more affordable generic options.
Generic versions of Novo Nordisk's blockbuster weight-loss drugs are expected to be available in Canada within months, following the expiration of patents. Experts believe these affordable alternatives will enhance access, shift societal views on weight loss, and alleviate financial pressures on the healthcare system.
Mar 26, 2026
Bristol-Myers Squibb shares rise following broader Opdivo approvals and advancements in AI initiatives.
Bristol-Myers Squibb shares rose 2.6% to $58.95 following FDA's expanded approvals for its cancer drug Opdivo, enhancing its market position in blood cancer treatments. The company reported a 10.3% year-to-date gain and a $26.4 billion growth portfolio. Additionally, a partnership with insitro aims to develop AI-driven therapies for ALS, signaling a strategic pivot in neurology.
Mar 26, 2026
AstraZeneca plc's shares are under examination due to challenges in its oncology pipeline and delays in regulatory approvals.
AstraZeneca plc faces market volatility due to delays in Phase III trial data for its Enhertu combination study in HER2-low breast cancer, pushing expectations to Q3 2026. The stock, listed on the London Stock Exchange, has seen a dip amid concerns over FDA timelines impacting 40% of revenue. Key drugs include Tagrisso and Imfinzi, with ongoing competition and patent challenges.
Mar 26, 2026
Merck is close to finalizing a $6 billion deal to acquire Terns Pharma in order to enhance its cancer treatment offerings, according to the Financial Times.
Merck has announced its acquisition of Terns Pharmaceuticals for $6.7 billion as it prepares for the impending patent expiration of its top-selling drug, Keytruda, in 2028. This strategic move aims to address the anticipated revenue decline following Keytruda's patent loss, which has been a leading immunotherapy treatment.
Mar 26, 2026
Chinese manufacturers of weight-loss medications challenge international leaders following the expiration of Novo Nordisk's patent.
China is set to approve at least 10 new weight-loss drugs, including Hengrui Medicine's ribupatide and Innovent Biologics' mazdutide, as the market is projected to reach $14 billion by 2030. Novo Nordisk's semaglutide, which lost patent protection, generated $35 billion globally last year. Both new drugs show greater weight-loss efficacy than semaglutide in phase 3 trials.
Mar 26, 2026
Slim profits and a streamlined CEO: Exploring the Novo Nordisk phenomenon - AFR
Novo Nordisk's CEO, Mike Doustdar, revealed that he lost 25 kilograms through traditional methods 16 years ago, prior to the introduction of popular weight loss drugs like Ozempic and Wegovy, which are classified as GLP-1s.
Mar 26, 2026
Is India poised to become a hub for weight-loss pharmaceuticals? - Finshots
India is poised to become a major exporter of affordable GLP-1 weight-loss drugs, following the expiration of Novo Nordisk's semaglutide patents. Generics could be priced up to 60% lower, enhancing access for millions with diabetes and obesity. However, challenges in manufacturing, cold-chain logistics, and competition from China may hinder India's ambitions in this burgeoning market.
Mar 26, 2026
India Takes Action Against Generic Obesity Medications as Market Overwhelmed with Copies Following Patent Expiration
Health authorities are warning of misuse risks as prices for obesity drugs, particularly those containing semaglutide, drop sharply in India following patent expirations. The Ministry of Health has raised concerns over the unregulated sale of generic GLP-1 drugs, urging that they be used only under medical supervision. Inspections have intensified to combat violations in pharmacies and online sales.
Mar 26, 2026
China's Market for Obesity Medications Expected to Exceed 20 Trillion Won Within Four Years
China's anti-obesity drug market, driven by the patent expiration of Novo Nordisk's semaglutide (Wegovy, Ozempic), is projected to exceed 20 trillion won by 2030. The entry of generics and biosimilars is expected to intensify competition, significantly lowering prices and expanding patient access, despite concerns over quality control and market saturation.
Mar 26, 2026
CDT Equity Enhances Tapinarof Patent Portfolio with Two Additional Filings
CDT Equity Inc. has filed two new patent applications to expand its intellectual property portfolio for tapinarof, a drug approved for psoriasis and atopic dermatitis. The patents cover a combination therapy and novel cocrystal forms, potentially enhancing efficacy and market reach. This move aligns with growing demand for innovative topical therapies in dermatology.
Mar 26, 2026
Lexaria's Strong Patent Collection Expands Further - TheNewswire
Lexaria Bioscience Corp. has been granted five new patents, including two for diabetes treatments utilizing GLP-1 drugs. The patents, part of Lexaria's ongoing R&D efforts, enhance its intellectual property portfolio, which now includes 65 patents globally. CEO Richard Christopher highlighted the significance of these achievements in the competitive GLP-1 industry.
Mar 26, 2026
Lexaria Expands Its Strong Patent Collection - Yahoo Finance
Lexaria Bioscience Corp. has been granted five new patents, including two for diabetes treatments using GLP-1 drugs. The patents, part of Lexaria's ongoing R&D efforts, enhance its intellectual property portfolio, which now includes 65 patents. CEO Richard Christopher highlighted the significance of these achievements in the competitive GLP-1 industry.
Mar 26, 2026
Lexaria Expands Its Strong Patent Collection - TradingView
Lexaria Bioscience Corp. has been granted five new patents, including two for diabetes treatments utilizing GLP-1 drugs. The patents, part of Lexaria's ongoing R&D efforts, enhance its intellectual property portfolio, which now includes 65 patents globally. CEO Richard Christopher highlighted the significance of these achievements in the competitive GLP-1 industry.
Mar 25, 2026
GSK plc shares face significant challenges due to pipeline uncertainties, patent expirations, and changes in strategy.
GSK plc faces significant challenges as key patents, including those for Shingrix and Arexvy, approach expiration, potentially leading to over £5 billion in annual revenue losses by 2030. The company is focusing on oncology and immunology, with promising candidates like Blenrep and depemokimab. Investors are closely watching GSK's execution amid competitive pressures and pipeline uncertainties.
Mar 25, 2026
Korea Aims for $1 Billion in Major Pharmaceuticals and 30 Trillion Won in Technology Exports
The South Korean government is launching a strategy to develop pharmaceutical and biotech companies capable of producing blockbuster drugs with annual sales of $1 billion. The initiative aims for 30 trillion won in technology exports by 2030, focusing on commercialization and global expansion. The plan includes funding, improved research infrastructure, and enhanced collaboration with global firms to foster innovation.
Mar 25, 2026
Court ruling favors cancer patients by permitting generic drugs - Juta MedicalBrief
The Supreme Court of Appeal has ruled that the generic prostate cancer medication Enzutrix will remain available at an affordable price, following a patent dispute with the Regents of the University of California over Xtandi. The court prioritized public interest, allowing Eurolab to continue producing Enzutrix, which is crucial for uninsured cancer patients.
Mar 25, 2026
FDA Sends Warning Letter to ImmunityBio Regarding 'Deceptive and Misleading' Statements About Bladder...
The FDA has issued a warning letter to ImmunityBio Inc. for promoting its bladder cancer drug Anktiva with false and misleading claims that exaggerate its benefits. The agency's action highlights concerns over the accuracy of the company's marketing practices.
Mar 25, 2026
Merck agrees to acquire Terns Pharmaceuticals for $6.7 billion - STAT News
Merck announced plans to acquire Terns Pharmaceuticals for $6.7 billion, valuing Terns at $53 per share. This acquisition aims to enhance Merck's cancer drug pipeline, particularly as it faces impending patent loss on its leading immunotherapy, Keytruda. Terns' stock surged six-fold in six months, driven by the potential of its leukemia treatment, TERN-701.
Mar 25, 2026
Dr. Reddy's generic weight-loss medication Olymviq will not be available in the market until Friday, according to Delhi News.
Dr. Reddy’s Laboratories (DRL) launched its generic semaglutide, branded as 'Obeda', in India following the expiration of Novo Nordisk's patent. However, DRL's other version, 'Olymviq', is under legal scrutiny for potential trademark infringement. The Delhi High Court has mandated DRL to maintain status quo until March 27, amid concerns over phonetic similarities to Novo Nordisk's 'Ozempic'.
Mar 25, 2026
Merck Acquires Terns for $6.7 Billion Amid Anticipation of Keytruda Patent Expiration and Promising Leukemia Treatment
Merck has acquired Terns Pharmaceuticals for approximately $6.7 billion, gaining access to TERN-701, a promising mid-stage leukemia drug. Analysts estimate TERN-701 could generate over $4 billion in peak sales, enhancing Merck's oncology portfolio ahead of Keytruda's loss of exclusivity in 2028. The deal, approved by both companies, is expected to close in the second quarter.
Mar 25, 2026
Eli Lilly and the 'social responsibility' associated with GLP-1 medications - STAT News
Merck has announced its acquisition of Terns Pharma for $6.7 billion, valuing Terns at $53 per share, a 6% premium. Terns' stock surged six-fold in six months, driven by the promising potential of its leukemia drug, TERN-701, and speculation about its attractiveness as a takeover target.
Mar 25, 2026
Novo Nordisk files lawsuit against Dr. Reddy's regarding Ozempic trademark | Business News - Mint
Novo Nordisk has initiated legal action against Dr. Reddy’s Laboratories to block the launch of a generic semaglutide product named "Olymviq," claiming it is too similar to its weight-loss drug Ozempic. The Delhi High Court has temporarily halted Dr. Reddy’s rollout until the case is heard, amid a surge of generics following semaglutide's patent expiration in India.
Mar 25, 2026
LLY vs. ABBV: Which Pharmaceutical Company May Provide Greater Growth Potential by 2026?
Eli Lilly (LLY) and AbbVie (ABBV) are prominent U.S. drugmakers with strong growth prospects. Lilly's GLP-1 drugs, Mounjaro and Zepbound, significantly boost its revenues, while AbbVie thrives with Skyrizi and Rinvoq post-Humira. Both companies face challenges, but Lilly is favored for growth potential, while AbbVie offers attractive valuation and stability.
Mar 25, 2026
Merck set to purchase Terns Pharmaceuticals in a $6.7 billion agreement - The Edge Malaysia
Merck & Co has agreed to acquire Terns Pharmaceuticals Inc for $6.7 billion, gaining access to Terns' promising leukaemia treatment, TERN-701. The deal, approved by both companies, comes as Merck faces patent expiration for its top-selling cancer drug, Keytruda. Terns' shares rose 5.4% following the announcement, while Merck's shares increased slightly.
Mar 25, 2026
Ozempic becomes available in generic form for millions globally - Juta MedicalBrief
Novo Nordisk's weight loss drugs, Ozempic and Wegovy, are losing patent protection in India, China, and other countries, allowing generics to enter the market. This shift could democratize access to these medications, previously limited to wealthier individuals. Generic versions are expected soon, with prices potentially dropping to $15 a month, compared to $349 in the U.S.
Mar 25, 2026
Could the Recent Label Expansion of BMY's Opdivo Enhance Its Immuno-Oncology Portfolio? - TradingView
Bristol Myers Squibb (BMY) has received FDA and European Commission approvals for expanded uses of its immuno-oncology drug Opdivo. The FDA approved Opdivo with doxorubicin, vinblastine, and dacarbazine for untreated stage III or IV classical Hodgkin lymphoma (cHL), while the EC approved it with brentuximab vedotin for select pediatric patients. These expansions enhance Opdivo's market potential in oncology.
Mar 25, 2026
Emerging affordable generic weight-loss medications set to intensify rivalry among leading brands.
Generic versions of semaglutide, the active ingredient in popular weight-loss drugs Ozempic and Wegovy, are set to disrupt the market with prices up to 70% lower. While this could expand access to treatments for diabetes and obesity, doctors urge caution due to potential risks from unsupervised use. Novo Nordisk, the original manufacturer, is prepared for increased competition as over 40 Indian firms plan to launch similar products.
Mar 25, 2026
Dr. Reddy's Launch of 'Olympiq' Halted Due to Similarity with Ozempic Name - Whalesbook
The Delhi High Court has temporarily blocked Dr. Reddy's Laboratories from launching its drug 'Olympiq' due to trademark infringement concerns with Novo Nordisk's Ozempic. The court's order, effective until Friday, raises challenges for Dr. Reddy's entry into the competitive GLP-1 market. The company must respond by Friday on whether it will abandon the 'Olympiq' brand.
Mar 25, 2026
Merck Set to Purchase Terns Pharmaceuticals for $6.7 Billion - Bloomberg.com
Merck & Co. has announced its acquisition of Terns Pharmaceuticals Inc. for $6.7 billion, securing a new leukemia treatment amid the impending patent expiration of its top-selling cancer drug. The deal includes a cash payment of $53 per share, representing a 6% premium over Terns' recent closing price.
Mar 25, 2026
Merck purchases cancer biotechnology firm Terns in a $6 billion agreement - Capital Brief
Merck has announced its acquisition of Terns Pharmaceuticals for USD6 billion in cash, paying USD53 per share. This move aims to bolster Merck's portfolio ahead of the 2028 patent expiry of its oncology drug Keytruda. The deal reflects a 31% premium over recent stock prices, continuing Merck's strategy of expanding through significant acquisitions.
Mar 24, 2026
India's drug regulatory authority enhances monitoring of illegal weight-loss medication sales.
India's drug regulator has intensified surveillance against unauthorized sales of weight-loss drugs following the launch of cheaper generic versions of Ozempic and Wegovy by local companies like Dr Reddy’s, Zydus, and Sun Pharma. The Central Drugs Standard Control Organization (CDSCO) is inspecting entities for violations amid concerns over misuse and health risks associated with these medications.
Mar 24, 2026
Pharmaceutical companies prepare to launch weight-loss medications as prices decrease following patent expirations.
Domestic pharmaceutical companies are rapidly entering the weight-loss drug market following the patent expiry of semaglutide. Companies like Sun Pharma, Zydus Lifesciences, and Dr Reddy’s Laboratories have launched cheaper versions, reducing treatment costs by 50-90%. Analysts predict the GLP-1 market could reach ₹12,000 crore in five years, with over 40 companies expected to introduce new brands.
Mar 24, 2026
Proper monitoring: Ensuring safety is vital for the success of weight-loss medications - Business Standard
Recent scandals involving Indian-manufactured cough syrups, which resulted in child fatalities in Central Asia and Africa, highlight serious concerns over drug quality and regulation in India. With a significant portion of generics expected to be subcontracted, the risk of counterfeiting remains high, with estimates suggesting that 28% of urban Indian drugs may be spurious, particularly affecting antibiotics and cancer treatments.
Mar 24, 2026
LXRX Shares Rise Following NVO's Launch of Phase I Trial for Collaborative Obesity Medication - TradingView
Lexicon Pharmaceuticals (LXRX) shares rose 5.1% after Novo Nordisk (NVO) began a phase I study of LX9851, an oral obesity treatment. The study will assess LX9851's safety and efficacy in 96 participants, with results expected by Q1 2027. LXRX could earn up to $1 billion in milestone payments from NVO, which will manage development and commercialization.
Mar 24, 2026
Novo Nordisk Pursues Expansion Beyond Its Leading Medications with New Trial for Obesity Treatment
Novo Nordisk has initiated a Phase 1 trial for its oral obesity drug LX9851, aiming to diversify beyond its GLP-1 drugs like Wegovy and Ozempic amid pricing pressures and a significant stock decline. The drug, developed through a partnership with Lexicon Pharmaceuticals, targets fat storage regulation and may enhance weight loss when combined with existing treatments.
Mar 24, 2026
India cautions against the potential abuse of affordable weight-loss medications with the introduction of Ozempic generics.
India's Health Ministry has raised concerns over the unregulated use of weight-loss drugs, particularly generic versions of semaglutide, the active ingredient in Ozempic and Wegovy, following patent expiry. With prices as low as $15 per dose, the Ministry warns of serious health risks from unsupervised use and has initiated actions to prevent unauthorized sales.
Mar 24, 2026
Do you believe Novo Nordisk will struggle in the GLP-1 market? Their recent drug approval might suggest otherwise...
Regulators have approved Wegovy HD, a higher-dose version of Novo Nordisk's weight loss drug, which showed an average weight loss of 20.7% in clinical trials. This approval may help Novo Nordisk regain market share in the competitive GLP-1 market, despite its stock facing bearish sentiment and a projected revenue decline.
Mar 24, 2026
Vessels stuck in the Strait of Hormuz, the expiration of the Semaglutide patent, and additional updates: A weekly summary in five visuals.
The patent for Semaglutide, used in Novo Nordisk's diabetes drugs Ozempic and Wegovy, expired, allowing cheaper generics to enter the market. Prices for the lowest dose are expected to drop significantly, expanding access for patients in India. Novo Nordisk and Eli Lilly are also investing in oral formulations to enhance supply.
Mar 24, 2026
India's drug regulatory authority enhances monitoring of illegal weight-loss medication sales - prohibits
India's drug regulator has intensified surveillance against unauthorized sales of weight-loss drugs following the launch of cheaper generic versions of Ozempic and Wegovy by local companies like Dr Reddy’s, Zydus, and Sun Pharma. The Central Drugs Standard Control Organization (CDSCO) is inspecting entities for violations amid concerns over misuse and health risks associated with these medications.
Mar 24, 2026
With the rising popularity of GLP-1 medications, maintaining healthy habits remains essential - WDEF
Mar 24, 2026
Generic Semaglutide Launches in India, Offering Significant Price Cuts
India's market for weight-loss and diabetes drugs has surged with the launch of generic semaglutide, originally developed by Novo Nordisk. Glenmark, Natco, Eris, Zydus, Sun Pharma, and Dr. Reddy’s have introduced affordable versions, reducing costs by 70-90%. This accessibility is expected to double sales of GLP-1 drugs, currently valued at ₹1,500 crore, enhancing treatment for obesity and Type 2 diabetes.
Mar 24, 2026
Pharmaceutical companies prepare to launch weight-loss medications as patents come to an end | The Morning Standard - Magzter
Domestic pharmaceutical companies are launching weight-loss drugs following the recent expiration of the patent on semaglutide, a key ingredient in popular diabetes and obesity treatments. Companies like Sun Pharma, Zydus Lifesciences, and Dr Reddy’s Laboratories are introducing their own versions, intensifying competition in the market.
Mar 24, 2026
Impact of Middle East Conflict on the Pharmaceutical Industry Beyond Oil and Pharmaceuticals
Military actions in the Middle East have disrupted global pharmaceutical supply chains, particularly affecting the UK, which relies heavily on generic drugs. Rising transport costs and delivery delays threaten to cause drug shortages, warns Medicines UK. Russia's reliance on Iranian drugs like SinnoVex, Arioseven, and Melitide is also at risk, though alternatives exist.
Mar 24, 2026
India Strengthens Regulations on Generic GLP-1 Weight Loss Medications - Whalesbook
India's drug regulator, the DCGI, is intensifying oversight of GLP-1 weight-loss drugs, particularly following the expiration of Novo Nordisk's semaglutide patent. Over 40 local companies, including Sun Pharma and Dr. Reddy's Laboratories, have launched generics, leading to significant price drops. However, compliance with strict regulations is crucial for market access and long-term success amidst rising competition and safety concerns.
Mar 24, 2026
TempraMed Enhances Global IP Portfolio with Approval of Patent in China
TempraMed Technologies Ltd. has received a significant milestone with the grant of a Chinese patent for its VIVI Box™ multi-medication storage platform, enhancing its global IP strategy. The patent, covering core innovations, was granted on March 17, 2026, and supports the company's commercialization efforts in Asia's healthcare market, with plans to launch the VIVI Box™ by the end of 2026.
Mar 24, 2026
India Enhances Regulations on GLP-1 Medications Following Concerns Over Misuse After Semaglutide Patent Expiration
India's drug regulator is enhancing surveillance on GLP-1 weight loss drugs, particularly after the patent expiry of Semaglutide, due to rising concerns over misuse and unauthorized sales. Authorities are tightening checks to ensure proper medical supervision. Additionally, the pharma sector faces challenges as input costs for key ingredients like paracetamol increase, impacting margins for smaller manufacturers.
Mar 24, 2026
BioNxt Moves into Commercialization Stage with Worldwide Patent Coverage and U.S. Fast Track Status
BioNxt Solutions Inc. has announced significant advancements in its commercialization strategy for its sublingual drug delivery platform, particularly its lead product BNT23001, a cladribine oral thin film targeting multiple sclerosis and myasthenia gravis. The company has secured a robust global patent portfolio and is transitioning into commercialization, focusing on partnerships and licensing opportunities to enhance patient compliance and drug delivery efficacy.
Mar 24, 2026
UP Chief Secretary Calls for Online Codeine Monitoring as Kanpur SIT Uncovers Interstate Operation
Uttar Pradesh Chief Secretary SP Goyal has mandated the establishment of an online tracking system for codeine-based cough syrup to combat the rising illegal sales and diversion, following revelations from a Kanpur SIT investigation into an interstate racket.
Mar 24, 2026
Rajya Sabha: Government Outlines Comprehensive Strategy to Combat Fake Medications Using QR Codes
The Union Government has announced a multi-faceted strategy to combat counterfeit drugs, including the implementation of QR codes, Good Manufacturing Practice (GMP) reforms, and over 860 enforcement actions. This initiative aims to enhance the quality and safety of medicines distributed throughout India.
Mar 24, 2026
Patent expiration leads to affordable Ozempic alternatives in Telangana, DCA cautions against usage.
The Telangana Drugs Control Administration has issued a public advisory against unsupervised use of semaglutide formulations, including Ozempic and Wegovy, following the drug's patent expiry. With prices dropping significantly, the DCA warns of serious health risks from self-medication and mandates that semaglutide be prescribed by qualified specialists. Illegal sales and promotions are strictly prohibited.
Mar 23, 2026
India is introducing affordable weight-loss medications, while Novo Nordisk is relying on its brand strength to maintain its leading position.
The launch of generic versions of Novo Nordisk's GLP-1 weight-loss drug, semaglutide, in India has begun, with Sun Pharmaceutical and Dr. Reddy's Laboratories offering prices up to 80% lower than Novo's. This follows the expiration of Novo's patent, raising concerns about its market share amid increasing competition. Analysts suggest Novo may need to cut prices to retain its position.
Mar 23, 2026
Novo Nordisk India Encounters Surge of Generic Semaglutide Following Patent Expiration | Whalesbook
Novo Nordisk India faces increased competition as its patent for semaglutide expires, enabling Indian firms like Dr Reddy's Laboratories and Sun Pharma to launch generics priced 50% to 80% lower. The company plans to adapt by cutting prices and forming partnerships, emphasizing patient access while maintaining its market presence in the $1 billion diabetes and obesity drug market.
Mar 23, 2026
Merz and Uexküll succeed as the Federal Court of Justice confirms the validity of fampridine patents.
Merz Therapeutics has successfully upheld its patents EP 536 and EP 548, which cover the dosing regimen for fampridine, the active ingredient in Fampyra, aimed at improving walking ability in multiple sclerosis patients. The German Federal Court of Justice dismissed nullity suits from Ratiopharm and Teva, allowing Merz to pursue damages claims against generic competitors in Germany.
Mar 23, 2026
Goodwin Advises Pharmakon Advisors on $250 Million Debt Arrangement with Zenas BioPharma
Pharmakon Advisors has entered a five-year, up to $250 million senior secured debt facility with Zenas BioPharma, aimed at supporting the development of a bifunctional monoclonal antibody for IgG4-related disease. The initial $75 million will be issued at closing, with additional funds contingent on regulatory conditions related to obexelimab.
Mar 23, 2026
India Poised to Introduce Affordable Alternatives to Ozempic as Patent Protections End - IndiaWest News
India is poised to launch generic versions of semaglutide, following the expiration of Novo Nordisk A/S's patents on March 27. Natco Pharma Ltd. plans to offer a semaglutide injection for $14 per month, significantly lower than Novo's Wegovy. Over 42 manufacturers may introduce more than 50 brands, driven by rising diabetes and obesity rates in the country.
Mar 23, 2026
Novartis Assures Expansion Amid Significant Patent Expirations - I Generally Concur (NYSE:NVS)
Novartis (NVS) has announced a $2 billion acquisition of Pikavation Therapeutics, potentially rising to $3 billion with milestones, to enhance its pipeline with SNV4818, a pan-mutant-selective PI3Kα inhibitor for HR+/HER2- breast cancer. Despite the strategic move, Novartis shares fell nearly 10% following the announcement, reflecting investor concerns amid competition with Eli Lilly's similar drug, STX-478.
Mar 23, 2026
Market for Generic Medications: Integration of Personalized Medicine and Pharmacogenomic Guidance...
The global generic drugs market reached USD 389.0 billion in 2024, projected to grow to USD 674.9 billion by 2033, driven by patent expirations and AI advancements. Notable companies include Teva Pharmaceuticals, Mylan, and Alembic Pharmaceuticals, which recently gained FDA approval for Carbamazepine tablets. Hikma Pharmaceuticals plans a USD 1 billion investment to enhance U.S. manufacturing capabilities.
Mar 23, 2026
Affordable Ozempic surge raises fresh worries about the risks associated with GLP-1 medications - India Today
India's pharmaceutical market is witnessing a significant shift with the launch of over nine generic versions of semaglutide, the active ingredient in drugs like Ozempic, following its patent expiry. Major Indian companies, including Sun Pharma and Dr Reddy’s, are entering the market, reducing costs dramatically. However, new studies raise concerns about cardiovascular risks associated with discontinuing GLP-1 therapies, emphasizing the need for careful patient management.
Mar 23, 2026
Zoetis Inc. at KeyBanc Healthcare Forum: Aiming for a $4 Billion Renal Market and a $170 Share Price
Zoetis Inc. (ZTS) is adapting its strategy amid slowing veterinary visits and increased competition for its dermatology drug, Apoquel. CEO Kristin Peck announced a shift towards long-acting injectables like Cytopoint. Despite challenges, the livestock division is thriving, and Zoetis is leveraging AI for future therapies, including a potential kidney disease drug. The stock is currently priced at $116, with a target of $167.
Mar 23, 2026
Novo Nordisk Addresses Patent Expiration and Improved Drug Authorization - Ad-hoc-news.de
Novo Nordisk has received FDA approval for Wegovy HD, a higher-dose version of its weight-loss drug semaglutide, which shows improved efficacy. However, the company faces challenges in India as its semaglutide patent expired, leading to impending generic competition from firms like Sun Pharma and Dr. Reddy's Laboratories. This dual situation impacts Novo Nordisk's market outlook for 2026.
Mar 23, 2026
With the rising popularity of GLP-1 medications, maintaining healthy habits remains essential.
A recent KFF survey reveals that 1 in 8 U.S. adults are using GLP-1 drugs, like Novo Nordisk's Wegovy, for weight loss. Experts emphasize that while these medications can aid in weight loss, combining them with lifestyle changes—such as diet and exercise—is crucial for maximizing health benefits and minimizing side effects.
Mar 23, 2026
Indian Firms Introduce Affordable Alternatives to Well-Known Weight Loss Medications - Fine Day Radio
Following the patent expiration of semaglutide in India, several pharmaceutical companies, including Sun Pharmaceutical, Dr Reddy’s Laboratories, and Zydus Lifesciences, have launched affordable alternatives to Ozempic and Wegovy, reducing costs by about 70%. Analysts predict over 40 companies will enter the market, targeting the $100 billion global obesity treatment sector.
Mar 23, 2026
With the rising popularity of GLP-1 medications, maintaining healthy lifestyle choices remains essential - ABC News
The use of anti-obesity drugs like Novo Nordisk's Wegovy and Zepbound is rising, with 1 in 8 U.S. adults currently taking them. Experts emphasize that while these GLP-1 medications aid weight loss, combining them with healthy lifestyle changes is crucial for maximizing benefits and minimizing side effects.
Mar 23, 2026
Part II: Competition Intensifies to Find Alternatives to Semaglutide | Major Pharmaceutical Companies
Novo Nordisk faces new challenges following the expiration of its core semaglutide patent in India last week. The company, known for its successful diabetes and weight loss drug, is now strategizing its next steps in the competitive pharmaceutical landscape.
Mar 23, 2026
Summary: Indian pharmaceutical companies are introducing more affordable alternatives to Novo's Ozempic and Wegovy.
Several Indian generic drugmakers have launched affordable versions of Novo Nordisk's diabetes drug Ozempic and weight-loss drug Wegovy, following the expiration of the semaglutide patent in India. Companies like Sun Pharmaceutical, Dr. Reddy's Laboratories, and Zydus Lifesciences are offering treatments at prices reduced by about 70%, targeting a global obesity market projected to reach $100 billion.
Mar 23, 2026
DCGI Takes Action Against 90 Unauthorized Fixed-Dose Combinations - Drug Regulation
India's drug regulator, DCGI, has flagged 90 unapproved fixed-dose combination (FDC) drugs, including cough syrups, vitamins, and diabetes medications, for sale without central approval. The agency has instructed state and Union Territory drug controllers to take immediate action to address this public health risk.
Mar 23, 2026
Launch of Ozempic Generic in India Set for 2026: Brands, Pricing, and Accessibility - Deccan Herald
Novo Nordisk's blockbuster weight loss drug, Ozempic, is set to lose patent protection in India, China, and other countries, paving the way for generic versions and potentially making the medication accessible to billions at lower prices.
Mar 22, 2026
The worldwide market for obesity treatments is beginning to show signs of decline, attributed to the presence of extremely low-cost options.
The global obesity treatment market faces disruption as Indian companies Eris Life Sciences and Dr. Redis Laboratories launch low-cost generic drugs, 'Sunday' and 'Obeda,' following the patent expiration of semaglutide, the main ingredient in Hugo Bee. Prices are expected to drop significantly, increasing accessibility and demand in developing markets.
Mar 22, 2026
South Africa may gain advantages as India initiates a worldwide shift in the pricing of weight-loss medications.
India is set to launch low-cost generic semaglutide injections, including drugs like Ozempic and Wegovy, following the expiration of key patents. This move is expected to significantly reduce prices, expanding access to obesity treatments in middle-income countries. Major firms, including Zydus Lifesciences, are preparing for rapid market entry, potentially increasing patient numbers dramatically.
Mar 22, 2026
Widespread Antibiotic Resistance Genes Indicate a Critical Public Health Emergency in Urban Areas - Medication Regulation
A recent metagenomic study highlights a critical public health crisis in India, revealing that sewage in major cities contains a widespread reservoir of antibiotic resistance genes (ARGs). This alarming finding underscores the urgent need for action to address the potential spread of these resistance genes among bacteria in urban wastewater.
Mar 22, 2026
Affordable Wegovy Generics Surge in Market Following Expiration of Patents in India
The expiration of semaglutide patents has led to a surge of ultra-cheap generics from Indian companies, including Eris Lifesciences' "Sunday" and Dr. Reddy's "Obeda," priced significantly lower than Wegovy. Analysts predict prices could drop to around $15 monthly, expanding access to obesity treatments. Novo Nordisk faces pressure as competition intensifies, particularly in markets without patent protections.
Mar 22, 2026
Affordable Weight-Loss Medications in India: A Significant Change in the Battle Against 'Diabesity' - PUNE PULSE
The expiry of the patent for semaglutide, a key drug for diabetes and weight loss, is set to revolutionize treatment in India by allowing affordable generics. Over 40 companies are expected to launch these drugs, potentially reducing costs by 50-60%. However, experts warn of misuse and stress the importance of medical supervision for safe use.
Mar 22, 2026
Indian pharmaceutical company introduces affordable generics of Ozempic following patent expiration - Arab News Pakistan
India's pharmaceutical industry has begun launching generic versions of Ozempic, following the expiration of Novo Nordisk's patent on semaglutide. Companies like Sun Pharmaceutical, Dr. Reddy’s, Alkem, and Zydus are offering the diabetes and weight-loss medication at prices starting at $15 per dose, significantly lower than the original's $20-$50 cost, expanding access for patients.
Mar 22, 2026
India Experiences Affordable Ozempic Availability - ScoopWhoop
The patent for semaglutide, the active ingredient in Novo Nordisk's weight-loss drugs Ozempic and Wegovy, has expired in India, allowing local manufacturers like Mankind Pharma, Sun Pharmaceutical, and Lupin to produce generics. Prices for these generics could drop by up to 50%, increasing access for millions. However, concerns about potential misuse and the need for regulation persist.
Mar 22, 2026
Enhanced Pharmacovigilance Required as Generic GLP-1 Medications Launch in India - The News Mill
As patents on GLP-1 drugs for type 2 diabetes and obesity expire, Indian pharmaceutical companies are set to launch affordable generics. Experts, including Dr. V Mohan, emphasize the need for strict pharmaco vigilance and qualified prescriptions to ensure safety. The CDSCO has warned against direct advertising of these medications to the public, highlighting the importance of professional guidance.
Mar 22, 2026
Launch of Generic Semaglutide in India Cuts Prices by 50-90% - Drug Regulatory Authority
Generic versions of semaglutide have launched in India following the expiration of Novo Nordisk's patent, resulting in price reductions of 50-90%. Leading domestic pharmaceutical companies have quickly received approvals from the DCGI to market these branded generics, making the medication more accessible to patients.
Mar 22, 2026
India aims to combat worldwide obesity through affordable weight-loss injections - Oman Observer
India is set to launch low-cost generic versions of weight-loss drugs like Ozempic, following the expiration of key patents on semaglutide. This move is expected to increase access to obesity treatments in middle-income countries, with over 50 brands anticipated to enter the market. Eli Lilly's Mounjaro is currently the top-selling drug in India, but generics could significantly lower treatment costs.
Mar 22, 2026
India aims to combat worldwide obesity through affordable weight-loss injections.
India is set to launch low-cost generic versions of weight-loss drugs like Ozempic and Mounjaro (tirzepatide) following the expiration of key patents. This move is expected to increase access to treatments, with over 50 brands anticipated to enter the market. The demand for these drugs is high, as obesity rates rise in India, where treatment costs currently limit access.
Mar 22, 2026
Novo Nordisk A/S shares encounter FDA alerts regarding GLP-1 medications as competition intensifies.
Novo Nordisk A/S faces challenges from recent FDA warnings regarding its GLP-1 treatments, including Ozempic and Wegovy, which highlight safety communication and manufacturing issues. As competition intensifies from Eli Lilly and Pfizer, the company’s market leadership is at risk. Despite these hurdles, Novo's strong pipeline and strategic investments aim to maintain its position in the growing obesity treatment market.
Mar 22, 2026
Alkem Laboratories Introduces Most Affordable Semaglutide Injection in India | Health and Me
Alkem Laboratories is set to launch a semaglutide injection under the brand names Semasize, Obesema, and Hepaglide, priced at a weekly cost of Rs 450, positioning it as one of the most affordable options in the market.
Mar 22, 2026
Affordable generic versions of Ozempic are introduced in India following the expiration of Novo Nordisk's patent.
Natco Pharma plans to launch a semaglutide injection at a competitive price of 1,290 rupees per month in India, following the patent expiry of Novo Nordisk's weight-loss drug. With over 42 manufacturers expected to introduce generic versions, the Indian market is set for a price war, potentially expanding the weight-loss market to $1 billion.
Mar 22, 2026
Indian pharmaceutical company introduces affordable generics of Ozempic following patent expiration - Arab News
India's pharmaceutical industry has begun launching generic versions of Ozempic, following the expiration of Novo Nordisk's patent on semaglutide. Companies like Sun Pharmaceutical, Dr. Reddy’s, Alkem, and Zydus are offering the drug at prices starting at $15 per dose, significantly lower than the original's $20-$50 cost. This move is expected to increase access and prescriptions for diabetes and weight management.
Mar 22, 2026
Importance of safety indicators as Semaglutide gains popularity - The New Indian Express
Novo Nordisk's patent for Semaglutide, a key ingredient in its diabetes and weight-loss drugs Ozempic and Wegovy, expired in India, leading to a dramatic price drop of 70-90%. Indian firms are set to launch generics priced between ₹1,300 and ₹4,000, targeting a massive market of millions with diabetes and obesity.
Mar 22, 2026
Mounjaro Expected to Surpass Keytruda as the Best-Selling Medication by 2030 - Seoul Economic Daily
Eli Lilly's obesity drug Mounjaro is projected to become the top-selling drug by 2030, surpassing Keytruda, developed by MSD (Merck). Mounjaro's sales are expected to reach $34 billion, while Keytruda's sales may drop to $17 billion due to patent expirations and increasing demand for obesity treatments. Other contenders include Ozempic, Skyrizi, and Dupixent.
